Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06128629 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06128629 · ClinicalTrials.gov record · last posted 2026-03-27

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Name: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) — clinical trial record (NCT06128629)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorIntellia Therapeutics

Started2023-12-13

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Amendment record 31 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 31 times since 2023-11-08; most recent amendment 2026-03-23. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2026-03-23

Status change Active, Not Recruiting→Recruitingv31

2025-11-24

Status change Recruiting→Active, Not Recruitingv30

2023-12-13

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT06128629
Lead Sponsor	Intellia Therapeutics Collaborators: Regeneron Pharmaceuticals
Conditions	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Enrollment	1,200 participants
Start Date	2023-12-13
Primary Completion	2027-12 (estimated)
Study Completion	2028-04 (estimated)
Updated on ClinicalTrials.gov	2026-03-27